Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Annaly Capital Management, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Annaly Capital Management, Inc. trades at $22.59 (market cap $16.63B). The key difference: Annaly Capital Management, Inc. is far larger — about 3.7× ACADIA Pharmaceuticals Inc.'s market cap, and Annaly Capital Management, Inc. pays a 13.22% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NLY | |
|---|---|---|
Market Cap | $4.49B | $16.63B |
Sector | Health | Financials |
52-Week High | $28.06 | $24.40 |
52-Week Low | $20.06 | $19.47 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 13.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Annaly Capital Management (NLY) trades at $22.69, up 0.58% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 7.42, ROE of 15.61%, and consistent earnings beats in recent quarters. Recent dividend increases to $0.75 per share and positive analyst coverage highlight income appeal. The company maintains solid liquidity despite significant investing outflows.
NLY presents a compelling income opportunity with a 13.2% dividend yield and analyst consensus target of $24.40. However, risks include interest rate sensitivity, high leverage (debt-to-asset ratio of 23.55), and volatile cash flow patterns. The stock offers 7.5% upside potential but requires monitoring of Federal Reserve policy impacts on mortgage REITs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
